Live Breaking News & Updates on Parkinsonian Disorder
Stay updated with breaking news from Parkinsonian disorder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
U.S. now open for enrollmentof rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollmentat Vanderbilt University Medical Center in Nashville, Tennessee. "Vanderbilt University has been a tremendous partner for our ATH434 clinical development program, and we are very excited to utilize their expertise as our first U.S. trial site," said David Stamler, M.D., Chief Executive Officer, Alterity. "ATH434 is a potential disease modifying treatment for individuals living with MSA, a rapidly progressive Parkinsonian disorder with no approved treatment. The opening o ....
U.S. now open for enrollmentof rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollmentat Vanderbilt University Medical Center in Nashville, Tennessee. "Vanderbilt University has been a tremendous partner for our ATH434 clinical development program, and we are very excited to utilize their expertise as our first U.S. trial site," said David Stamler, M.D., Chief Executive Officer, Alterity. "ATH434 is a potential disease modifying treatment for individuals living with MSA, a rapidly progressive Parkinsonian disorder with no approved treatment. The opening o ....
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received approval in Australia from the St. Vincent's Hospital Melbourne. ....